000			01707 a2200469 4500
005			20250511212109.0
264		0	_c19910426
008			199104s 0 0 eng d
022			_a0340-7004
024	7		_a10.1007/BF01741330 _2doi
040			_aNLM _beng _cNLM
100	1		_aWeiskirch, L M
245	0	0	_aPhorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. _h[electronic resource]
260			_bCancer immunology, immunotherapy : CII _c1991
300			_a353-63 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnimals
650	0	4	_aAntigens, Differentiation, T-Lymphocyte _xphysiology
650	0	4	_aCD8 Antigens
650	0	4	_aCell Line
650	0	4	_aCytotoxicity, Immunologic _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aIn Vitro Techniques
650	0	4	_aIonomycin _xpharmacology
650	0	4	_aLymphocyte Depletion
650	0	4	_aMelphalan _xtherapeutic use
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aPhagocytes _xphysiology
650	0	4	_aPlasmacytoma _xdrug therapy
650	0	4	_aT-Lymphocytes _xdrug effects
650	0	4	_aTetradecanoylphorbol Acetate _xpharmacology
650	0	4	_aThymoma _xdrug therapy
650	0	4	_aTime Factors
700	1		_aBaumgartel, B A
700	1		_aBarker, E
700	1		_aMokyr, M B
773	0		_tCancer immunology, immunotherapy : CII _gvol. 32 _gno. 6 _gp. 353-63
856	4	0	_uhttps://doi.org/10.1007/BF01741330 _zAvailable from publisher's website
999			_c1907228 _d1907228